GO
Loading...

Actavis Inc

More

  • Oct 20- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter. Other bidders for the Belgian consumer healthcare company include Perrigo Co and private German drugmaker Boehringer Ingelheim GmBH, the sources told Bloomberg.

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc, according to two people familiar with the matter. The hedge fund, which earlier supported a deal with Valeant, told Allergan CEO David Pyott...

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals, according to two people familiar with the matter. The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire, the sources said.

  • Reuters Business News Schedule at 1800 GMT/4 PM ET Sunday, 12 Oct 2014 | 4:06 PM ET

    NEW YORK- For Federal Reserve officials already worried about a persistent lack of U.S. wage and price growth, one corner of the bond market may be suggesting even more reason for alarm. The Treasury Inflation Protected Securities market is suggesting price stagnation may be just around the corner. NEW YORK- U.S. regulators are asking banks for more detail on...

  • NEW YORK/ BOSTON, Oct 10- Fidelity Investments, the largest shareholder in Actavis Plc, has increased its holdings in takeover-target Allergan in recent months and would be supportive of a potential merger between the two drugmakers, according to people familiar with the matter. The additions would likely make Fidelity the No.8 shareholder in Allergan,...

  • Oct 9- Botox maker Allergan Inc said on Thursday it expects to report third-quarter profit that is more than 20 percent higher than it previously anticipated, which it said bolsters its contention that an unsolicited takeover offer by Valeant Pharmaceuticals Inc undervalues the company. Allergan has criticized the company's model of growing through...

  • Oct 9- Botox maker Allergan Inc lifted its third-quarter profit estimate and said the updated forecast showed that Valeant Pharmaceuticals Inc's takeover offer undervalued the company. "Today's announced expectations for the third quarter and updated future outlook further demonstrate that there is a vast value gap between Valeant's offer and the...

  • Oct 8- If Actavis Plc proceeds with a purchase of Botox maker Allergan Inc for potentially more than $60 billion, it will represent the biggest bet yet by one of the traditional generic drugmakers on the upside of expanding branded medicine holdings. Reuters reported on Tuesday that Actavis plans to approach Allergan about a potential merger, providing an...

  • NEW YORK, Oct 8- Earlier this week, Canada's Valeant Pharmaceuticals International Inc appeared to have its plan to buy Botox maker Allergan Inc all mapped out. However, Valeant's well-laid plans appeared to run into trouble this week, when rival drugmaker Actavis Plc came back into the picture as a possible white knight for Allergan. Meanwhile, a separate person...

  • NEW YORK, Oct 7- Actavis Plc plans to make a new approach for Allergan Inc about a potential merger, as the Botox maker warms up to the possibility of a sale, said people familiar with the matter. Actavis, which held informal conversations with Allergan in recent months about a possible combination, would like to take a hard look at buying the company and could reach...

  • "Markets are reflecting nervousness around third-quarter earnings given the strong dollar and a very weak macro environment in Europe," said Jim Russell, senior equity strategist for U.S. Hewlett-Packard posted the S&P 500' s largest gains, up 4.7 percent to $36.87 after it said it would split into two listed companies and eliminate another 5,000 jobs.

  • NEW YORK, Oct 3- Salix Pharmaceuticals Ltd, citing a "changed political environment," said on Friday it had scrapped a deal with Italy's Cosmo Pharmaceuticals SpA that would have allowed it to shift its tax base from the United States to Europe. In recent months, Salix has also been pursued by Allergan Inc as the Botox maker seeks to fend off a $53 billion hostile...

  • Raleigh, North Carolina- based Salix, which makes drugs for gastrointestinal disorders, said in July it would merge with Cosmo's Irish subsidiary, a deal that would allow Salix to move its tax domicile abroad in a practice known as inversion. The development path of the pipeline continued in the meantime, so this termination has no effect on value creation, "said...

  • Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. It will compete with Nektar Therapeutics and AstraZeneca Plc's oral drug Movantik, approved by the FDA earlier this month for the same patient population.

  • Sept 29- Salix Pharmaceuticals Ltd said the U.S. Food and Drug Administration approved an expanded use of its constipation treatment. Salix, which is merging with Cosmo Pharmaceuticals SpA's Irish subsidiary, is in talks with Allergan Inc and Actavis Plc about a potential sale, sources have told Reuters in recent weeks.

  • Sept 26- T. Rowe Price, the second largest shareholder in Allergan Inc, said on Friday that it wants the company to hold off on making major moves before a Dec. 18 special shareholder meeting, and criticized the board's corporate governance.

  • NEW YORK, Sept 24- Actavis Plc has reached an agreement with New York's attorney general to keep selling a top Alzheimer's drug for 60 days so U.S. patients will not be forced to switch to a newer, more expensive form of the drug with additional patent protection.

  • CORRECTED-Actavis in buyout talks with Salix - CNBC Wednesday, 24 Sep 2014 | 10:16 AM ET

    Allergan Inc has also been in talks with Salix as it tries to fend off an unwanted bid from Valeant Pharmaceuticals Inc.. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.

  • Allergan in buyout talks with Actavis - CNBC Wednesday, 24 Sep 2014 | 9:54 AM ET

    Sept 24- Allergan Inc is in buyout talks with Actavis Plc in addition to Salix Pharmaceuticals Ltd, CNBC reported on Wednesday, as the company tries to fend off a takeover attempt by Valeant Pharmaceuticals Inc. Allergan has questioned the sustainability of Valeant's growth and business model and "opaque" financial disclosures.

  • Sept 23- Pfizer Inc has approached Dublin- based generic drugmaker Actavis Plc to express its interest in an acquisition, Bloomberg reported, citing people with knowledge of the matter. The companies are not currently in formal talks and Pfizer has not made an offer, the Bloomberg report said.